Abstract
The clinical characteristics of pertussis disease are highly dependent on the host’s basic immunity. Most if not all neonates and young infants (i.e., <3 months of age) of mothers who were not immunized against pertussis during pregnancy develop a cough when exposed to Bordetella pertussis, the causative agent of pertussis (or whooping cough). At this young age, infants are highly vulnerable for complicated disease, which includes apnea (in 49–58% of affected individuals), the need for supplemental oxygen (59–100%) and/or mechanical ventilation (27–100%), and pulmonary hypertension (11–39%). In accordance, most deaths due to B. pertussis infection occur in neonates and young infants with a case fatality rate of 1–3%.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, Messonnier NE, Clark TA, Martin SW, Patel M. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015;135:981–9.
Berkovic SF, Harkin L, McMahon JM, Pelekanos JT, Zuberi SM, Wirrell EC, Gill DS, Iona X, Mulley JC, Scheffer IE. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol. 2006;5:488–92.
Büttcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, de Menezes MR, Vermeer-de Bondt P, The Brighton Collaboration HHE Working Group. Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2007;25:5875–81.
Cherry JD. Epidemic pertussis and acellular pertussis vaccine failure in the 21st century. Pediatrics. 2015;135:1130–2.
Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Textbook of pediatric infectious diseases. 6th ed. Philadelphia: Saunders; 2009. p. 1683–706.
Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Fry NK, Ramsay M. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin Infect Dis. 2015;60:333–7.
Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96:557–66.
European Centre for Disease Prevention and Control (ECDC). Pertussis. Stockholm: ECDC. n.d.. Available from: ► http://ecdc.europa.eu/en/activities/surveillance/euvac/case_definition/Pages/pertusis.aspx.
Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, Heininger U, Schellekens J, Tan T, von König CH, Plotkin S, Global Pertussis Initiative. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin Infect Dis. 2004;39:1802–9.
Heininger U, Cherry JD. Pertussis immunisation in adolescents and adults – Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther. 2006;6:685–97.
Heininger U, André P, Chlibek R, Kristufkova Z, Kutsar K, Mangarov A, Mészner Z, Nitsch-Osuch A, Petrović V, Prymula R, Usonis V, Zavadska D. Comparative epidemiologic characteristics of pertussis in 10 central and Eastern European Countries, 2000–2013. PLoS One. 2016;11(6):e0155949.
Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway AL, Lee GM, Hambidge S, Jackson ML, Omer SB, McCarthy N, Nordin JD. Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. Vaccine. 2016;34:968–73.
Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367:1012–9.
Koepke R, Eickhoff JC, Ayele RA, Petit AB, Schauer SL, Hopfensperger DJ, Conway JH, Davis JP. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210:942–53.
Maertens K, Caboré RN, Huygen K, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine. 2016;34:142–50.
McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015;135:331–43.
Nieves D, Heininger U, Cherry J. Bordetella pertussis and other Bordetella spp. infections. In: Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO, editors. Remington and Klein’s infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia, PA: Elsevier Saunders; 2016. p. 598–616.
Urwyler P, Heininger U. Protecting newborns from pertussis – the challenge of complete cocooning. BMC Infect Dis. 2014;14(1):397. doi:10.1186/1471-2334-14-397.
Winter K, Cherry JD, Harriman K. Effectiveness of prenatal Tdap vaccination on pertussis severity in infants. Clin Infect Dis. 2017a;64(1):9–14.
Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum Tdap vaccination in preventing infant pertussis. Clin Infect Dis. 2017b;64(1):3–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Heininger, U. (2017). Pertussis Vaccines. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-319-59952-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-59952-6_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59950-2
Online ISBN: 978-3-319-59952-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)